Clinical effectiveness in first-episode patients

Ohlsen, R. I., O'Toole, M. S., Purvis, R. G., Walters, James Tynan Rhys ORCID: https://orcid.org/0000-0002-6980-4053, Taylor, T. M., Jones, H. M. and Pilowsky, L. S. 2004. Clinical effectiveness in first-episode patients. European Neuropsychopharmacology 14 (4) , S445-S451.

Full text not available from this repository.

Abstract

Managing patients with first-episode schizophrenia is a challenging task for psychiatrists. Early diagnosis and effective intervention are vital to achieving long-term positive clinical outcomes among first-episode patients. Although these patients are the most responsive to treatment, they are also more susceptible to adverse events. The efficacy and improved tolerability associated with the newer atypical antipsychotics means that these drugs can be used successfully in the treatment and long-term management of schizophrenia from the onset of illness. However, as well as managing the symptoms of the disease, pharmacological treatments need to meet the broader requirements of clinical effectiveness that encompass all of the outcome domains associated with schizophrenia. This article will discuss available data on atypical antipsychotics in first-episode patients and present the primary results from the F1RST (Southwark first-onset psychosis) study, which examined the use of quetiapine for the first-line management of schizophrenia as part of a specialist episode psychosis service.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Neuroscience and Mental Health Research Institute (NMHRI)
Subjects:	R Medicine > R Medicine (General)
Publisher:	Elsevier
ISSN:	0924-977X
Last Modified:	31 Oct 2022 10:07
URI:	https://orca.cardiff.ac.uk/id/eprint/83756

Citation Data

Cited 20 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item